General Information |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2021-05-10 |
| Clinical feature |
| Label |
ovarian cancer |
| Link |
http://purl.obolibrary.org/obo/DOID_2394 |
| Description |
A female reproductive organ cancer that is located_in the ovary.; Xref MGI.
OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCT2033200431 |
| Other study identifiers |
| Name |
jRCT2033200431 |
| Description |
Japan Registry of Clinical Trials (jRCT) |
|
| Source weblink |
https://jrct.niph.go.jp/en-latest-detail/jRCT2033200431 |
| Public contact |
| Email |
GPC3-CAR_core@east.ncc.go.jp |
| Public email |
GPC3-CAR_core@east.ncc.go.jp |
| Last name |
Clinical Trial Coordinating Office |
| Phone |
+81-4-7133-1111 |
| Country |
|
| Address freetext |
National Cancer Center Hospital East 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba, 277-8577, Japan |
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Recruiting |
| Estimated number of participants |
18 |
